Plain-English translation of NCT06045013 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
Carpal tunnel syndrome causes pain, numbness, and tingling in the hand and wrist. This study is testing whether adding methylprednisolone acetate (a corticosteroid) to a dextrose injection makes the treatment more effective than dextrose alone. Both injections are guided by ultrasound to reach the nerve precisely.
Carpal tunnel syndrome can be very uncomfortable and limit daily activities. Doctors want to find the best injection approach to relieve symptoms—to understand whether adding the corticosteroid medication improves outcomes compared to dextrose by itself.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive one of two injections: either dextrose alone or dextrose combined with methylprednisolone. A doctor will use ultrasound imaging to guide a single injection into the carpal tunnel area of your affected wrist. The procedure is done at the hospital clinic, and you will be monitored to see how well the injection relieves your symptoms over time.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
Croatia
Phase
Large-scale testing
Sponsor
General and Veteran Hospital Croatian Pride Knin
Collaborators
Clinical Hospital Centre Zagreb, School of Public Health Andrija Štampar
Enrollment target
~70 participants
Started
September 2023
Primary completion
January 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in September 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Igor Begović, MD
General and Veteran Hospital "Croatian Pride" Knin, Croatia
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.